the decision is basically imminent, meaning that sometime from now until March 31 we will get a pr on the direction of this drug. It could happen after hours today, next week, or next month. So, to answer your question, no, you might not have to wait 2 months, you might very well get an answer sooner rather than later.
The original guidance that was stated before the end of the year has not changed. We will get a PR in less than 60 days on path forward. She said the bad weather resulted in some rescheduling. There are multiple outcomes here as you can imagine. I am not sure what it is going to look like, but we'll at least get a path forward before end of Q1.
Within 7 days there will be a PR from the company regarding the opening of the enrollment
Update from patient #4 in the next 30, which would include the 45 day evaluation
Update from patient #5 in the next 30, first eval
2 patients will be enrolled under emergency access within 30 days
within 60 days new protocol will be announced, with total number of patients
I am looking higher than that 2.5-3 with real significant data, that will send it over 1.00 gain easily. Because it is the dosing range data, at the high end of the dose the results could be spectacular. Could double in premarket, especially with low float.
hopefully, but only a couple of cents the last couple of days, would like to see 1.5+ going forward, results on the blood drug should be out soon
Looks like the next piece of news is the partial p2 results on the blood drug. This would show maximum dosing and maybe effectiveness? If this shows positive results, the stock could potentially go up 50%
Sentiment: Strong Buy
Rick, Thanks for the note. In order for a site to be open for enrollment, many requirements must be met including having product onsite ready to be used on a subject. InVivo has no control over selecting the patient. It’s up to the principal investigator. Hope that helps,Brian Brian Luque
Business Development &Investor Relations Manager
InVivo Therapeutics Corporation
So for those of you that keep saying that Invivo cherry picks the first patient to make it "look successful" shove it
Sentiment: Strong Buy